MNK Apr 2020 7.000 call

OPR - OPR Delayed Price. Currency in USD
0.4000
0.0000 (0.00%)
As of 2:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4000
Open0.4500
Bid0.3500
Ask0.8500
Strike7.00
Expire Date2020-04-17
Day's Range0.4000 - 0.4500
Contract RangeN/A
Volume14
Open Interest43
  • Companies to Watch: Blackstone looks to expand, Mallinckrodt reaches settlement in opioid crisis, record weekend for Amazon and Walmart
    Yahoo Finance Video

    Companies to Watch: Blackstone looks to expand, Mallinckrodt reaches settlement in opioid crisis, record weekend for Amazon and Walmart

    The Blackstone Group, Mallinckrodt, Amazon, Walmart, General Motors and Universal are the companies to watch.

  • Zacks.com featured highlights include: Mallinckrodt, Sony and Public Storage
    Zacks

    Zacks.com featured highlights include: Mallinckrodt, Sony and Public Storage

    Zacks.com featured highlights include: Mallinckrodt, Sony and Public Storage

  • Top Ranked Growth Stocks to Buy for October 22nd
    Zacks

    Top Ranked Growth Stocks to Buy for October 22nd

    Top Ranked Growth Stocks to Buy for October 22nd

  • PR Newswire

    Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week

    STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, is proud to celebrate Respiratory Care Week (October 20-26, 2019), and honor the role of respiratory therapists in providing critical care to patients in respiratory distress. There are more than 134,000 respiratory therapists in the U.S. Respiratory therapists work closely as part of medical teams to evaluate, treat and care for patients with breathing or other cardiopulmonary disorders. With more than 80 percent working in hospital settings, they play critical roles in neonatal intensive care units (NICU), emergency rooms, air transport and other areas of acute and critical care.

  • J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos
    Zacks

    J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos

    J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.

  • PR Newswire

    Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

    -- Late-breaker abstract, "A North American Randomized Controlled Trial (RCT) of Terlipressin plus Albumin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)" -- STAINES-UPON-THAMES, United ...

  • Top 3 ROE Stocks to Profit as Earnings Season Heats Up
    Zacks

    Top 3 ROE Stocks to Profit as Earnings Season Heats Up

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • Will Mallinckrodt Continue to Surge Higher?
    Zacks

    Will Mallinckrodt Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Mallinckrodt.

  • Is the Options Market Predicting a Spike in Mallinckrodt (MNK) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Mallinckrodt (MNK) Stock?

    Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

  • Benzinga

    Opioid Drug Companies Rally On Hopes of Broader Settlement

    Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday  Wall Street Journal report that said three opioid drug distributors are in talks with ...

  • PR Newswire

    Mallinckrodt to Report Earnings Results for Third Quarter 2019

    A conference call for investors will begin at 8:30 a.m. Eastern Time. Callers will need to provide the Conference ID of 6080969. Through an audio replay: A replay of the call will be available beginning at 11:30 a.m. Eastern Time on Tuesday, Nov. 5, 2019, and ending at 11:30 a.m. Eastern Time on Tuesday, Nov. 19, 2019.

  • J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
    Zacks

    J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

    J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

  • American City Business Journals

    Why St. Louis stocks are trailing stocks nationally this year

    St. Louis stocks far underperformed the national stock indexes through the first three quarters of the year, but almost a third of the local companies were up 20% or more.

  • The Market Tells Opioid Drugmakers to Settle Up
    Bloomberg

    The Market Tells Opioid Drugmakers to Settle Up

    (Bloomberg Opinion) -- The markets are sending a message to drugmakers facing opioid litigation: Settle up.Johnson & Johnson late Tuesday announced its first legal settlement over the pharmaceutical giant’s alleged role in spurring the opioid crisis, a modest $20 million deal with two Ohio counties. The agreement will see it avoid a risky trial later this month and the company’s stock rose as much as 3.6% in early trading. J&J’s deal came a day after a report that drugmakers may use Purdue Pharma’s bankruptcy as a model for a broader settlement, news that briefly boosted smaller companies including Mallinckrodt PLC, Teva Pharmaceutical Industries Ltd, and Endo International PLC. The profusion of litigation, the size of the addiction crisis, and public fury have created a liability of unknown size that could take years to resolve. Thousands of lawsuits remain, and a global deal that resolves a big chunk of those suits will be challenging to negotiate. J&J’s settlement cracks the door, however, and investors want resolution. Getting something done and moving on should be a priority for drugmakers over pinching pennies.  Banding together could help ensure that no drugmaker would be left behind to fight through every lawsuit or face a potential liability disproportionate to its relative role in the crisis. It won’t be cheap, and it won’t be easy, but it would be worth the effort.A global settlement, even if it involves a substantial cash payout, would go a long way toward helping drugmakers move forward from the crisis, while investors would finally be able to put a number on the liability instead of fearing the uncertain result of every individual trial. A settlement also could reduce the risk of bankruptcy for indebted members of the group, cutting another asymmetric risk. As for the other side, the parties affected by the crisis should fight aggressively for a large settlement. The amount of money needed to combat the crisis and build a real treatment infrastructure in America demands it. Beyond that, it’s worth fighting for a figure large enough to deter the kind of behavior and negligence that allegedly spurred the crisis. That doesn’t mean they should disdain a global settlement and the idea of compromise. A broad deal may be governments' best avenue to get cash quickly so they can help people in need as soon as possible. Stretching the fight out may not result in a larger payout, and could result in some communities getting nothing. We’re still a long way from a significant deal; many states oppose even the single-company version of Purdue’s bankruptcy. Hopefully, both sides will realize the benefits of avoiding a multi-year battle and make further progress. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • JNJ moves to dodge opioid bullets, but other drug names face uncertainty
    Yahoo Finance

    JNJ moves to dodge opioid bullets, but other drug names face uncertainty

    Opioid litigation increasingly affecting credit outlooks for drug makers and distributors.

  • Opioid Makers Gain on View They’ll Use Purdue Deal as Model
    Bloomberg

    Opioid Makers Gain on View They’ll Use Purdue Deal as Model

    (Bloomberg) -- Makers of prescription painkillers are climbing higher after Dow Jones reported that the companies are looking to use Purdue Pharma LP’s bankruptcy as a model to settle their own lawsuits.Mallinckrodt Plc and Endo International Plc jumped Tuesday morning as Wall Street gauged what shape their settlements might take. The two, plus drugmaker Teva Pharmaceutical Industries Ltd., are facing similar claims related to their role in sparking the opioid crisis.Shares of Mallinckrodt and Endo rose by at least 10% while Teva gained a much as 7.1%. Mallinckrodt has shed more than 90% of its market value in the past year and Endo and Teva are down 78% and 66%, respectively.Companies that distributed opioids -- McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. -- edged higher as the Purdue idea may signal progress in resolving lawsuits.(Updates share movement in third, fourth paragraph)To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Mallinckrodt Up on Settlement Agreement With Ohio Counties
    Zacks

    Mallinckrodt Up on Settlement Agreement With Ohio Counties

    Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.

  • PR Newswire

    Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)

    STAINES-UPON-THAMES, United Kingdom, Oct. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, today announced positive top-line findings from its observational registry to assess treatment patterns and response to Acthar® Gel (repository corticotropin injection) in reducing the clinical impact of disease exacerbations in patients with multiple sclerosis (MS) relapse. Mallinckrodt plans to share the data at an upcoming medical meeting. MS is a chronic, degenerative disease that can cause numerous impairments, including fatigue, balance/coordination issues, numbness or tingling, vision problems, muscle spasms, tremors and emotional changes, and some people with MS experience relapses while on standard therapies1.

  • Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits: WSJ
    Reuters

    Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits: WSJ

    Endo, J&J, Teva Pharmaceutical Industries Ltd, Allergan Plc and Mallinckrodt Plc - are looking to enact a global settlement of the litigation that would be implemented through Purdue's Chapter 11 case, the WSJ reported, citing a person familiar with the matter. The mechanism, if successful, would allow the companies to contribute money into a trust set up through the bankruptcy in exchange for a complete release from liability, according to the report.

  • Reuters

    UPDATE 1-Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits -WSJ

    Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person familiar with the matter. Five drugmakers battling the cases - Endo, J&J, Teva Pharmaceutical Industries Ltd, Allergan Plc and Mallinckrodt Plc - are looking to enact a global settlement of the litigation that would be implemented through Purdue's Chapter 11 case, the WSJ reported, citing a person familiar with the matter.

  • Blackstone, Mallinckrodt, Amazon, Walmart: Companies to watch
    Yahoo Finance

    Blackstone, Mallinckrodt, Amazon, Walmart: Companies to watch

    The Blackstone Group, Mallinckrodt, Amazon, Walmart, General Motors and Universal are the companies to watch.

  • Barrons.com

    Mallinckrodt Stock Is Rising on Opioid Settlement

    (MNK) shares rose Monday morning as the drugmaker said it had completed an opioid settlement announced in early September. The $30 million deal releases Mallinckrodt from a federal trial set to begin Oct. 21, in which the Ohio counties of Cuyahoga and Summit are pursuing more than a dozen pharmaceutical companies involved in the manufacture and sale of opioids. In early trading, Mallinckrodt’s stock (ticker: MNK) was up 2.5%, to $2.30.

  • MarketWatch

    Mallinckrodt stock surges after agreement to pay $24 million to Ohio counties as part of opioid litigation settlement

    Shares of Mallinckrodt PLC surged 4% in premarket trading Monday, after the drug maker said it reached a settlement agreement in connection with opioid litigation with the Ohio counties of Cuyahoga and Summit, in which the drug maker will pay $24 million in cash, provide $6 million in generic products and provide a $500,000 payment in two years in recognition of the counties' time and expenses. Under terms of the agreement, all named Mallinckrodt entities will be dismissed with prejudice from the lawsuit, and the value of the settlement should not be extrapolated to any other opioid-related claims. The stock has plunged 75.5% over the past three months while the S&P 500 has gained 0.7%.

  • PR Newswire

    Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit

    Under the agreement, Mallinckrodt will pay $24 million in cash and provide $6 million in generic products, including addiction treatment products. It also will provide a $500,000 payment in two years in recognition of the counties' time and expenses.  Further, in the event of a comprehensive resolution of government-related opioid claims, Mallinckrodt has agreed that the two plaintiff counties will receive the value they would have received under such a resolution, less the payments described above. "Mallinckrodt is pleased to finalize this settlement agreement with the Cuyahoga and Summit Counties," said Mark Casey, Executive Vice President and Chief Legal Officer of Mallinckrodt.